Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

85.98 +1.37 (+1.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Incyte (INCY) Stock Is Up, What You Need To Know
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 2.4% in the afternoon session after Barclays initiated coverage on the stock with an Overweight rating, helping the shares... 
Via StockStory
Topics Economy
Tuesday's session: top gainers and losers in the S&P500 index
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday. 
Via Chartmill
1 Profitable Stock to Keep an Eye On and 2 We Question
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
13 Analysts Have This To Say About Incyte
 
Via Benzinga
Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer
Via Stocktwits
Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?
Analysts expect nearly 450% EPS growth in 2025, making execution on its core portfolio critical for sustaining the outperformance experienced so far YTD. 
Via MarketBeat
Incyte Corp (NASDAQ:INCY): A Prime Candidate for Value Investors Seeking Undervalued Stocks
Discover Incyte Corp (INCY), an undervalued biotech stock with strong profitability, solid financial health, and promising growth potential for value investors. 
Via Chartmill
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
S&P 500 Losers: 22 Stocks With Negative Returns Over Past 10 Years, And This One's Getting The Boot
The S&P 500 Index is up over 200% over the past decade, but 22 stocks have declined during that period, and one is set to be removed soon. 
Via Benzinga
Topics Stocks
Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
From Incyte
Via Business Wire
1 Mid-Cap Stock with Solid Fundamentals and 2 We Find Risky
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
2 Mooning Stocks with Exciting Potential and 1 We Ignore
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Immuno-Oncology Stocks Q2 In Review: Incyte (NASDAQ:INCY) Vs Peers
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Incyte (NASDAQ:INCY) and its peers. 
Via StockStory
Topics Artificial Intelligence
Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy Lawsuit
INCY Q2 Deep Dive: Product Launches and Pipeline Progress Underpin Revenue Growth
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 16.5% year on year to $1.22 billion. Its non-GAAP profit of... 
Via StockStory
1 Momentum Stock for Long-Term Investors and 2 Facing Challenges
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to new product launches, positive news, or even a dedicated social media... 
Via StockStory
Beyond The Numbers: 12 Analysts Discuss Incyte Stock
 
Via Benzinga
Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis
From Incyte
Via Business Wire
Incyte Corp (NASDAQ:INCY): A Value Investing Gem with Strong Valuation and Financial Stability
Incyte Corp (INCY) is a value investor's pick with a strong 9/10 Valuation Rating, low P/E ratios, solid financial health, and steady profitability in biotech. 
Via Chartmill
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?
The upgraded score means Gilead is now outperforming 96% of all stocks in terms of the most important stock-picking criteria. 
Via Investor's Business Daily
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday
 
Via Benzinga
The Analyst Verdict: Incyte In The Eyes Of 10 Experts
 
Via Benzinga
Top S&P500 movers in Tuesday's session
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session. 
Via Chartmill
Incyte (INCY) Stock Trades Up, Here Is Why
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 10.4% in the afternoon session after the company reported second-quarter financial results that beat analyst expectations and... 
Via StockStory
Topics Artificial Intelligence
Uncover the latest developments among S&P500 stocks in today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand
Incyte posts strong Q2 results driven by Jakafi and Opzelura growth, lifts 2025 guidance despite challenges in future product development. 
Via Benzinga
AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday?
Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events. 
Via Benzinga
Sanmina, Sarepta Therapeutics, Polaris, Celestica And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Which S&P500 stocks are moving before the opening bell on Tuesday?
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.